Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome
- PMID: 32157752
- DOI: 10.1111/iju.14205
Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome
Abstract
Objectives: To evaluate the renal function after adrenalectomy in patients with Cushing's syndrome in comparison with that in patients with primary aldosteronism.
Methods: This retrospective study included 35 patients with Cushing's syndrome and 51 patients with primary aldosteronism who underwent unilateral adrenalectomy and were followed up for >6 months. The renal function was analyzed before and after adrenalectomy using the estimated glomerular filtration rate. Postoperative renal impairment was defined as a >25% reduction in the estimated glomerular filtration rate from baseline at 1 month after adrenalectomy. Multivariate logistic regression analyses were carried out to examine whether the differences between Cushing's syndrome and primary aldosteronism increased the risk of postoperative renal impairment. Longitudinal changes were calculated starting 1 month after adrenalectomy using the linear mixed model.
Results: The mean estimated glomerular filtration rate in both groups significantly decreased at 1 month after adrenalectomy from baseline. Postoperative renal impairment was observed in four (11%) and 12 (24%) patients in the Cushing's syndrome and primary aldosteronism groups, respectively. Multivariate analysis showed that preoperative systolic blood pressure was independently associated with postoperative renal impairment, but not with the type of the disease. There was no significant increase or decrease in postoperative estimated glomerular filtration rate observed after the initial decrease after adrenalectomy in either group.
Conclusions: Patients with Cushing's syndrome show the same persistent renal impairment after adrenalectomy as that reported in patients with primary aldosteronism. Attention should be given to possible masked renal damage in clinical practice for the management of Cushing's syndrome.
Keywords: Cushing's syndrome; adrenalectomy; hyperaldosteronism; kidney function tests; renal insufficiency.
© 2020 The Japanese Urological Association.
Comment in
-
Editorial Comment to Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome.Int J Urol. 2020 May;27(5):400-401. doi: 10.1111/iju.14216. Epub 2020 Mar 11. Int J Urol. 2020. PMID: 32157717 No abstract available.
Similar articles
-
Laparoscopic adrenalectomy for Cushing's syndrome: comparison with primary aldosteronism.Surgery. 1995 Jan;117(1):11-7. Surgery. 1995. PMID: 7809824
-
Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy.Int J Urol. 2013 Jul;20(7):685-91. doi: 10.1111/iju.12029. Epub 2012 Nov 27. Int J Urol. 2013. PMID: 23190329
-
Factors associated with renal function change after unilateral adrenalectomy in patients with primary aldosteronism.Int J Urol. 2022 Aug;29(8):831-837. doi: 10.1111/iju.14905. Epub 2022 Apr 26. Int J Urol. 2022. PMID: 35474521
-
Primary aldosteronism concurrent with subclinical Cushing's syndrome: a case report and review of the literature.J Med Case Rep. 2020 Feb 20;14(1):32. doi: 10.1186/s13256-020-2353-8. J Med Case Rep. 2020. PMID: 32075693 Free PMC article. Review.
-
Adrenal Surgery for Cushing's Syndrome: An Update.Endocrinol Metab Clin North Am. 2018 Jun;47(2):385-394. doi: 10.1016/j.ecl.2018.01.004. Epub 2018 Apr 9. Endocrinol Metab Clin North Am. 2018. PMID: 29754639 Review.
Cited by
-
Renal safety of zoledronic acid in patients with osteoporosis: a retrospective study.Endocrine. 2024 Feb;83(2):459-465. doi: 10.1007/s12020-023-03567-5. Epub 2023 Nov 16. Endocrine. 2024. PMID: 37971631
References
-
- Ross EJ, Linch DC. Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2: 646-9.
-
- Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 2003; 88: 5593-602.
-
- Edwards CR, Stewart PM, Burt D et al. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2: 986-9.
-
- Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583-5.
-
- Funder JW, Mihailidou AS. Aldosterone and mineralocorticoid receptors: clinical studies and basic biology. Mol. Cell. Endocrinol. 2009; 301: 2-6.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical